Response by Pleva et al to Letter Regarding Article, "Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis: The Treatment of In-Stent Restenosis Study"
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Circulation: Cardiovascular Interventions |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1161/CIRCINTERVENTIONS.116.004304 |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | coronary restenosis; diabetes mellitus; drug-eluting stents; paclitaxel; stents |
| Description | We read with great interest the letter by Alfonso et al with comments to our study.1 We know the interesting results of the RIBS V study (Restenosis Intra-Stent of Bare-Metal Stents: Paclitaxel-Eluting Balloon vs. Everolimus-Eluting Stent). Contrary to RIBS V, we used everolimus-eluting stents (EES) with platinum-chromium metallic platform and a different primary end point, 12-month late lumen loss (LLL) in our study. |